Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Status:
Terminated
Trial end date:
2016-06-07
Target enrollment:
Participant gender:
Summary
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of
patients with recurrent unresectable head and neck squamous cell carcinoma.